Apollomics Inc., a biopharmaceutical company based in the Cayman Islands, has filed an amendment to its Form F-3 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The company, which specializes in the discovery and development of oncology therapies, is preparing for the proposed sale of securities to the public, which will commence after the effectiveness of the registration statement. The securities may include Class A Ordinary Shares, Debt Securities, Rights, Warrants, and Units, with a total offering amount of up to $200,000,000. Apollomics Inc. has its principal executive offices in Foster City, California, and operates through its U.S. headquarters and subsidiaries in mainland China. The company's Class A Ordinary Shares and warrants are listed...Show More

Apollomics Inc., a biopharmaceutical company based in the Cayman Islands, has filed an amendment to its Form F-3 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The company, which specializes in the discovery and development of oncology therapies, is preparing for the proposed sale of securities to the public, which will commence after the effectiveness of the registration statement. The securities may include Class A Ordinary Shares, Debt Securities, Rights, Warrants, and Units, with a total offering amount of up to $200,000,000. Apollomics Inc. has its principal executive offices in Foster City, California, and operates through its U.S. headquarters and subsidiaries in mainland China. The company's Class A Ordinary Shares and warrants are listed on the Nasdaq Capital Market under the symbols 'APLM' and 'APLMW,' respectively. As of April 17, 2024, the closing prices for the shares and warrants were $0.53 and $0.02, respectively. The company has not yet made any dividends or distributions to its parent companies or investors, and the transfer of funds between the company and its subsidiaries is subject to PRC government controls on currency conversion.